Xenon Pharmaceuticals (XENE) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 4:01 PM EDTXEN1101 End of Phase 2 Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022
Company-sponsored Phase 2 Clinical Trial Initiated to Evaluate XEN1101 for the Treatment of MDD
Conference Call at 4:30 pm ET Today
BURNABY, British Columbia, May 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals... More
